Skip to content

4559.T

ZERIA PHARMACEUTICAL CO.,LTD.

プライム · 医薬品 · 医薬品 · JP

JPY 1,992.00
−0.94%
Ask drillr

Year over year

Reported trailing growth

Revenue
+4.9%
EBITDA
EBIT
+1.3%
EPS
-3.6%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
+3.9%
EBITDA
EPS
+30.8%

Three-year CAGR

Revenue
+13.6%
EBITDA
+19.8%
EBIT
+24.2%
Net income
+35.9%
EPS
+37.0%
Free cash flow
+13.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026